Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 266 participants.
Also called NCT01663233
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 266 participants
- Sponsor
- Registry
-
NCT01663233
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, Japan, Malaysia, Philippines, South Korea, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT01663233. Randomized; triple masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2015-08-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine
- Condition
- Essential Hypertension
- Intervention (Drug)
- LCZ696
- Intervention (Drug)
- Amlodipine
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01663233- Content hash
608af3941540551018a01cbe2306e91465f984040585e3f75e6e81e73ab38824